Last reviewed · How we verify

NCT04969068

The Median Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg

Status unknown Phase 4 Last updated 10 January 2022
What this trial tests

Phase 4 trial testing Remimazolam in Anesthesia in 50 participants. Status unknown.

Timeline
23 July 2021
Primary endpoint
30 December 2021
30 December 2021

Quick facts

Lead sponsorTianjin Nankai Hospital
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposeother
Enrollment50
Start date23 July 2021
Primary completion30 December 2021
Estimated completion30 December 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Tianjin Nankai Hospital

Who can join

Adults 18 to 85, any sex, with Anesthesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Remimazolam has shown promising results for sedation in colonoscopy . Alfentanil is widely used in the analgesia of ERCP . The purpose of the study was to determine the median effective dose of remimazolam for duodenoscopy insertion during ERCP with alfentanil 10µg/kg.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Remimazolam

Trials testing the same drug.

Other recruiting trials for Anesthesia

Currently open trials in the same condition.

Other Tianjin Nankai Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04969068.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing